Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ninebiopharm Co. Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio involves 1 distinct examiner and 1 distinct art unit, indicating that the company's current patenting activity is focused on a specific technical niche. This concentration simplifies the oversight of the portfolio, as all pending matters are consolidated under a single examiner's review. The presence of 1 distinct art unit ensures that the technical arguments remain within a consistent regulatory framework.
The busiest examiner for Ninebiopharm Co. Ltd. is AUDET, MAURY A, who is assigned 1 pending office action. This 1 pending office action constitutes the entire pending workload for the company at this time. The presence of 1 distinct art unit suggests that the subject matter has been consistently categorized by the patent office. Practitioners can direct their efforts toward the specific requirements of AUDET, MAURY A to move the pending application toward a final resolution. Understanding the examination patterns of this specific official is key to navigating the 1 pending office action in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997804 | REGENTIDE-034 AND COMPOSITION FOR IMPROVING CONDITION OF SKIN, CONTAINING SAME | AUDET, MAURY A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997804 | REGENTIDE-034 AND COMPOSITION FOR IMPROVING CONDITION OF SKIN, CONTAINING SAME | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17997804 | REGENTIDE-034 AND COMPOSITION FOR IMPROVING CONDITION OF SKIN, CONTAINING SAME | AUDET, MAURY A | 1654 | §101 | Final Rejection | — | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial